Bioxcel Therapeutics is a biopharmaceutical company focused on innovative drug development to address unmet medical needs in the fields of neurology and psychiatry
Utilizing its proprietary artificial intelligence platform, the company aims to identify and advance novel therapeutics that can improve patient outcomes in challenging conditions such as agitation in Alzheimer's patients and cancer-related symptoms. Bioxcel's approach integrates data-driven decision-making and clinical research to bring forth potential treatments that enhance the quality of life for patients dealing with complex health issues.
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
USA News Group Commentary Issued on behalf of Avant Technologies Inc. Vancouver, BC – December 17, 2024 – USA News Group News Commentary – Artificial intelligence (AI) is on the brink of becoming a critical resource in healthcare, moving beyond its status as a novel concept. With over 800 FDA-cleared AI applications already in […]
BioXcel Therapeutics shares topline results from an Igalmi (dexmedetomidine) sublingual film study. The 180 mcg dose demonstrated favorable safety and efficacy in reducing agitation symptoms.
From no AI category losses in February, to 3 drops in March - now all 7 fell this week, clearly indicating that that the surge in AI stock prices that began back on October 31st is, indeed, over.
All but one of the 7 artificial intelligence stock categories that I analyze weekly increased in value this week. But two categories are still down MTD, suggesting that the surge in the artificial intelligence technology sector is slowing.
The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway.
BioXcel Therapeutics shares surge 25.1% as the company terminates its proposed public offering and shifts focus to upcoming FDA meeting and Phase 3 trial.
Tonix Pharmaceuticals (NASDAQTNXP ) is not just another biotech company. They're revolutionizing the CNS therapeutics landscape with groundbreaking advancements that address a critical need: effective treatments for the 26% of American adults suffering from Central Nervous System (CNS) disorders.
PALM BEACH, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Recent reports project that the anal cancer market will continue its recent growth through 2030. An article on the MD Anderson website. It said: “More than 8,000 people in the U.S. are diagnosed with anal cancer each year. Due to higher rates of the human papilloma virus, a key risk factor, it affects women more than men. If found early, the disease can be successfully treated. Several types of tumors may be found in the anus. While some of them are malignant (cancer), others are benign (not cancer) or precancerous (may develop into cancer). The main types of anal cancer are: Carcinoma in situ is early cancer or precancerous cells. They are only on the surface cells of the anal canal. This also may be called Bowen’s disease; Squamous cell cancer (carcinoma) forms in the cells that line the anus. This is the most common type of anal cancer; Adenocarcinomas develop in the glands around the anus; and Skin cancers, including basal cell and melanoma, often are found when they are in advanced stages.” A report from Market Research Future projected that: “The Anal cancer market is anticipated to reach USD 1,638.5 Million by 2030 at 8.6% CAGR… through 2030. It said: “Anal cancer is a rare type of cancer that begins in the anus, which is the orifice at the rectum's end. Anal cancer has one of the highest rates of occurrence and prevalence in the globe. Lifestyle issues, aging, and diet are thought to be the primary causes of anal cancer. According to the World Health Organization (WHO), an increase of roughly 70% in anal cancer cases is projected globally over the Anal Cancer Market Analysis period (2030). Squamous cell carcinoma, which develops from cells around or in the anal entrance or, in rare cases, in the anal canal, is the most common type of anal cancer. This malignancy is frequently linked to the human papillomavirus (HPV), with HPV malignancies or cervical cancers having a significant chance of progressing to anal cancer. Anal cancer has no specific symptoms; however, it might cause bleeding from the anal area, a tumor or swelling near the anus, or a change in bowel habits.” Active biotech and pharma companies in the markets this week include Oncolytics Biotech® Inc. (NASDAQONCY) (TSX: ONC), Exelixis, Inc. NASDAQ: EXELNASDAQEXEL)(NYSE: PFENYSEPFE, BioXcel Therapeutics, Inc. (NASDAQ: BTAINASDAQ), Bristol Myers Squibb (NYSE: BMYBMY).
